Learning How to Answer the Question ‘What Is ALS?’

Learning How to Answer the Question ‘What Is ALS?’

I remember the first time someone asked me, “What is ALS?” It was an awkward moment and the question caught me completely off guard. Why? Because only a few months earlier I had received an ALS diagnosis and was searching for the answer to that very question myself. “Um…

Northeast Community PTA Students Raise $1,200+ for ALS Research

For the last 15 years, students in the physical therapy assistant (PTA) program at Northeast Community College in Norfolk, Nebraska have participated in a local amyotrophic lateral sclerosis (ALS) event that seeks to raise awareness about the progressive neurodegenerative disorder — and raise the funds to fight it. This…

New Deal Helps Move Gene Therapy ET-101 Closer to Clinical Testing

Eikonoklastes Therapeutics and Forge Biologics have announced a new partnership to advance the development of ET-101, an experimental gene therapy for amyotrophic lateral sclerosis (ALS), toward clinical trial testing. Eikonoklastes acquired the rights to ET-101 from the University of California San Diego earlier this year. Under…

Analyses Support Design of COURAGE-ALS Trial of Reldesemtiv 

The COURAGE-ALS Phase 3 clinical trial, testing Cytokinetic’s experimental therapy reldesemtiv in people with amyotrophic lateral sclerosis (ALS), is expected to enroll patients who are most likely to benefit from the potential treatment. That’s according to a new analysis of data from an earlier Phase 2 study of reldesemtiv called…

Effector T-cell Levels May Predict Disease Progression, Survival

Higher levels of inflammatory immune cells called effector T-cells at the time of diagnosis are associated with faster disease progression and worse survival among people with amyotrophic lateral sclerosis (ALS), a new study indicates. In turn, greater numbers of regulatory T-cells, which work to dampen excessive immune responses, were…

How a Robot on Mars Improved My Attitude

I’ll admit that because I live with ALS, some of my past “Human vs. Automation” experiences have been, um, less than perfect. Touchpads that open automated doors don’t always work for me, and voice activation software doesn’t recognize my commands. But now, I have a new sense of…

Tofersen to Treat SOD1 ALS Under Review for European Union

The European Medicines Agency (EMA) has agreed to review an application seeking the approval of tofersen in treating amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, the therapy’s developer, Biogen, reported. “Today’s announcement is an important milestone for the ALS community in Europe where there is a tremendous need…